Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Ovarian Research
Published in: Journal of Ovarian Research 1/2017

Open Access 01-12-2017 | Research

The value of dynamic contrast–enhanced MRI in characterizing complex ovarian tumors

Authors: Hai-Ming Li, Jin-Wei Qiang, Feng-Hua Ma, Shu-Hui Zhao

Published in: Journal of Ovarian Research | Issue 1/2017

Login to get access

Abstract

Background

The study aimed to investigate the utility of dynamic contrast enhanced MRI (DCE-MRI) in the differentiation of malignant, borderline, and benign complex ovarian tumors.

Methods

DCE-MRI data of 102 consecutive complex ovarian tumors (benign 15, borderline 16, and malignant 71), confirmed by surgery and histopathology, were analyzed retrospectively. The patterns (I, II, and III) of time-signal intensity curve (TIC) and three semi-quantitative parameters, including enhancement amplitude (EA), maximal slope (MS), and time of half rising (THR), were evaluated and compared among benign, borderline, and malignant ovarian tumors. The types of TIC were compared by Pearson Chi-square χ 2 between malignant and benign, borderline tumors. The mean values of EA, MS, and THR were compared using one-way ANOVA or nonparametric Kruskal-Wallis test.

Results

Fifty-nine of 71 (83%) malignant tumors showed a type-III TIC; 9 of 16 (56%) borderline tumors showed a type-II TIC, and 10 of 15 (67%) benign tumors showed a type-II TIC, with a statistically significant difference between malignant and benign tumors (P < 0.001) and between malignant and borderline tumors (P < 0.001). MS was significantly higher in malignant tumors than in benign tumors and in borderline than in benign tumors (P < 0.001, P = 0.013, respectively). THR was significantly lower in malignant tumors than in benign tumors and in borderline than in benign tumors (P < 0.001, P = 0.007, respectively). There was no statistically significant difference between malignant and borderline tumors in MS and THR (P = 0.19, 0.153) or among malignant, borderline, and benign tumors in EA (all P > 0.05).

Conclusions

DCE-MRI is helpful for characterizing complex ovarian tumors; however, semi-quantitative parameters perform poorly when distinguishing malignant from borderline tumors.
Literature
1.
Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO classification of tumours of female reproductive organs. Lyon: IARC; 2014.
2.
Foti PV, Attinà G, Spadola S, Caltabiano R, Farina R, Palmucci S, et al. MR imaging of ovarian masses: classification and differential diagnosis. Insights Imaging. 2016;7(1):21–41.CrossRefPubMed
3.
Mohaghegh P, Rockall AG. Imaging strategy for early ovarian cancer: characterization of adnexal masses with conventional and advanced imaging techniques. Radiographics. 2012;32(6):1751–73.CrossRefPubMed
4.
Ovarian cancer: Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 1. 2015. NCCN Clinical Practice Guidelines in oncology.
5.
Helpman L, Beiner ME, Aviel-Ronen S, Perri T, Hogen L, Jakobson-Setton A, et al. Safety of ovarian conservation and fertility preservation in advanced borderline ovarian tumors. Fertil Steril. 2015;104(1):138–44.CrossRefPubMed
6.
Loizzi V, Selvaggi L, Leone L, Latorre D, Scardigno D, Magazzino F, et al. Borderline epithelial tumors of the ovary: experience of 55 patients. Oncol Lett. 2015;9(2):912–4.PubMed
7.
Ditto A, Martinelli F, Lorusso D, Haeusler E, Carcangiu M, Raspagliesi F. Fertility sparing surgery in early stage epithelial ovarian cancer. J Gynecol Oncol. 2014;25(4):320–7.CrossRefPubMedPubMedCentral
8.
Collinson F, Qian W, Fossati R, Lissoni A, Williams C, Parmar M, et al. Optimal treatment of early-stage ovarian cancer. Ann Oncol. 2014;25(6):1165–71.CrossRefPubMedPubMedCentral
9.
Thomassin-Naggara I, Bazot M, Daraï E, Callard P, Thomassin J, Cuenod CA. Epithelial ovarian tumors: value of dynamic contrast-enhanced MR imaging and correlation with tumor angiogenesis. Radiology. 2008;248(1):148–59.CrossRefPubMed
10.
Thomassin-Naggara I, Daraï E, Cuenod CA, Rouzier R, Callard P, Bazot M. Dynamic contrast-enhanced magnetic resonance imaging: a useful tool for characterizing ovarian epithelial tumors. J Magn Reson Imaging. 2008;28(1):111–20.CrossRefPubMed
11.
Li X, Hu LJ, Zhu LM, Sun XH, Sheng HQ, Zhai N, et al. The clinical value of dynamic contrast-enhanced MRI in differential diagnosis of malignant and benign ovarian lesions. Tumor Biol. 2015;36(7):5515–22.CrossRef
12.
Dilks P, Narayanan P, Reznek R, Sahdev A, Rockall A. Can quantitative dynamic contrast-enhanced MRI independently characterize an ovarian mass? Eur Radiol. 2010;20(9):2176–83.CrossRefPubMed
13.
Bernardin L, Dilks P, Liyanage S, Miquel ME, Sahdev A, Rockall A. Effectiveness of semi-quantitative multiphase dynamic contrast-enhanced MRI as a predictor of malignancy in complex adnexal masses: radiological and pathological correlation. Eur Radiol. 2012;22(4):880–90.CrossRefPubMed
14.
15.
Patel N, Harris AL, Gleeson FV, Vallis KA. Clinical imaging of tumor angiogenesis. Future Oncol. 2012;8(11):1443–59.CrossRefPubMed
16.
17.
Franiel T, Hamm B, Hricak H. Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer. Eur Radiol. 2011;21(3):616–26.CrossRefPubMed
18.
He DF, Ma DQ, Jin EH. The use of dynamic contrast enhanced MRI in differentiating between benign and malignant breast tumors and predicting the histologic grade for breast cancer patients. Chin J Radiol. 2012;46(12):1075–8.
19.
Ren J, Huan Y, Wang H, Chang YJ, Zhao HT, Ge YL, et al. Dynamic contrast-enhanced MRI of benign prostatic hyperplasia and prostatic carcinoma: correlation with angiogenesis. Clin Radiol. 2008;63(2):153–9.CrossRefPubMed
20.
Hansford BG, Peng Y, Jiang Y, Vannier MW, Antic T, Thomas S, et al. Dynamic contrast-enhanced MR Imaging curve-type analysis: Is it helpful in the differentiation of prostate cancer from health peripheral zone? Radiology. 2015;275(2):448–57.CrossRefPubMed
21.
Shan J, Xu JM, Gong JS, Wang XM, Xu HL, Feng XF. Value of dynamic enhanced MR imaging in the differential diagnosis of benign and malignant ovarian tumors. Chin J Radiol. 2003;37(11):1001–6.
22.
O’Connor JP, Jackson A, Parker GJ, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer. 2007;96(2):189–95.CrossRefPubMedPubMedCentral
23.
Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3(6):401–10.CrossRefPubMed
24.
Medeiros LR, Freitas LB, Rosa DD, Silva FR, Sliva LS, Birtencourt LT, et al. Accuracy of magnetic resonance imaging in ovarian tumor: a systematic quantitative review. Am J Obstet Gynecol. 2011;204(1):67. e1-10.CrossRefPubMed
Metadata
Title
The value of dynamic contrast–enhanced MRI in characterizing complex ovarian tumors
Authors
Hai-Ming Li
Jin-Wei Qiang
Feng-Hua Ma
Shu-Hui Zhao
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Ovarian Research / Issue 1/2017
Electronic ISSN: 1757-2215
DOI
https://doi.org/10.1186/s13048-017-0302-y

Other articles of this Issue 1/2017

Journal of Ovarian Research 1/2017 Go to the issue

Research

Optimal parameters for determining the LH surge in natural cycle frozen-thawed embryo transfers

Research

The value of DCE-MRI in assessing histopathological and molecular biological features in induced rat epithelial ovarian carcinomas

Research

Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort

Research

Enterolactone has stronger effects than enterodiol on ovarian cancer

Research

R-spondin2, a novel target of NOBOX: identification of variants in a cohort of women with primary ovarian insufficiency

Research

Circulatory microRNA 23a and microRNA 23b and polycystic ovary syndrome (PCOS): the effects of body mass index and sex hormones in an Eastern Han Chinese population